These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11244342)

  • 1. Type a syndrome of insulin resistance: anterior chamber anomalies of the eye and effects of insulin-like growth factor-I on the retina.
    Martin XD; Zenobi PD
    Ophthalmologica; 2001; 215(2):117-23. PubMed ID: 11244342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.
    Morrow LA; O'Brien MB; Moller DE; Flier JS; Moses AC
    J Clin Endocrinol Metab; 1994 Jul; 79(1):205-10. PubMed ID: 8027228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus.
    Vestergaard H; Rossen M; Urhammer SA; Müller J; Pedersen O
    Eur J Endocrinol; 1997 May; 136(5):475-82. PubMed ID: 9186267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus.
    Schalch DS; Turman NJ; Marcsisin VS; Heffernan M; Guler HP
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1563-8. PubMed ID: 8263142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year follow-up study of blood-retinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative diabetic retinopathy.
    Lobo CL; Bernardes RC; Figueira JP; de Abreu JR; Cunha-Vaz JG
    Arch Ophthalmol; 2004 Feb; 122(2):211-7. PubMed ID: 14769598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.
    Regan FM; Williams RM; McDonald A; Umpleby AM; Acerini CL; O'Rahilly S; Hovorka R; Semple RK; Dunger DB
    J Clin Endocrinol Metab; 2010 May; 95(5):2113-22. PubMed ID: 20233784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.
    Cusi K; DeFronzo R
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3077-84. PubMed ID: 10999789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-1 retinal microangiopathy in the pig eye.
    Danis RP; Bingaman DP
    Ophthalmology; 1997 Oct; 104(10):1661-9. PubMed ID: 9331208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.
    Thrailkill KM; Quattrin T; Baker L; Kuntze JE; Compton PG; Martha PM
    Diabetes Care; 1999 Apr; 22(4):585-92. PubMed ID: 10189536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
    Pennisi P; Gavrilova O; Setser-Portas J; Jou W; Santopietro S; Clemmons D; Yakar S; LeRoith D
    Endocrinology; 2006 Jun; 147(6):2619-30. PubMed ID: 16513827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.
    Zenobi PD; Jaeggi-Groisman SE; Riesen WF; Røder ME; Froesch ER
    J Clin Invest; 1992 Dec; 90(6):2234-41. PubMed ID: 1469083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes].
    Kato M
    Hokkaido Igaku Zasshi; 1998 Nov; 73(6):613-25. PubMed ID: 10036618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
    Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
    Clemmons DR; Sleevi M; Allan G; Sommer A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients.
    Jabri N; Schalch DS; Schwartz SL; Fischer JS; Kipnes MS; Radnik BJ; Turman NJ; Marcsisin VS; Guler HP
    Diabetes; 1994 Mar; 43(3):369-74. PubMed ID: 8314009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal neovascularization during treatment with IGF-1 for insulin resistance syndrome.
    Kitamei H; Yokoi M; Kase M; Ohno S
    Graefes Arch Clin Exp Ophthalmol; 2005 Jul; 243(7):715-7. PubMed ID: 15672252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.
    Nakae J; Kato M; Murashita M; Shinohara N; Tajima T; Fujieda K
    J Clin Endocrinol Metab; 1998 Feb; 83(2):542-9. PubMed ID: 9467572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A.
    Zenobi PD; Glatz Y; Keller A; Graf S; Jaeggi-Groisman SE; Riesen WF; Schoenle EJ; Froesch ER
    Eur J Endocrinol; 1994 Sep; 131(3):251-7. PubMed ID: 7921209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired growth in Rabson-Mendenhall syndrome: lack of effect of growth hormone and insulin-like growth factor-I.
    Longo N; Singh R; Griffin LD; Langley SD; Parks JS; Elsas LJ
    J Clin Endocrinol Metab; 1994 Sep; 79(3):799-805. PubMed ID: 8077364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.